Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Ephrin-B2–EphB4
cancer therapy
seed and soil
spinal bone metastasis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Jul 2021
27 Jul 2021
Historique:
received:
05
06
2021
revised:
21
07
2021
accepted:
23
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
9
9
2021
Statut:
epublish
Résumé
Tumor-endothelial cell interactions represent an essential mechanism in spinal metastasis. Ephrin-B2-EphB4 communication induces tumor cell repulsion from the endothelium in metastatic melanoma, reducing spinal bone metastasis formation. To shed further light on the Ephrin-B2-EphB4 signaling mechanism, we researched the effects of pharmacological EphB4 receptor stimulation and inhibition in a ligand-dependent/independent context. We chose a preventative and a post-diagnostic therapeutic window. EphB4 stimulation during tumor cell seeding led to an increase in spinal metastatic loci and number of disseminated melanoma cells, as well as earlier locomotion deficits in the presence of endothelial Ephrin-B2. In the absence of endothelial Ephrin-B2, reduction of metastatic loci with a later manifestation of locomotion deficits occurred. Thus, EphB4 receptor stimulation affects metastatic dissemination depending on the presence/absence of endothelial Ephrin-B2. After the manifestation of solid metastasis, EphB4 kinase inhibition resulted in significantly earlier manifestation of locomotion deficits in the presence of the ligand. No post-diagnostic treatment effect was found in the absence of endothelial Ephrin-B2. For solid metastasis treatment, EphB4 kinase inhibition induced prometastatic effects in the presence of endothelial Ephrin-B2. In the absence of endothelial Ephrin-B2, both therapies showed no effect on the growth of solid metastasis.
Identifiants
pubmed: 34360793
pii: ijms22158028
doi: 10.3390/ijms22158028
pmc: PMC8347368
pii:
doi:
Substances chimiques
EFNB2 protein, mouse
0
Ephrin-B2
0
Ligands
0
Neoplasm Proteins
0
Ephb4 protein, mouse
EC 2.7.10.1
Receptor, EphB4
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Pigment Cell Melanoma Res. 2010 Oct;23(5):684-7
pubmed: 20649938
Int J Cancer. 2012 Sep 1;131(5):E614-24
pubmed: 22161689
Cell Metab. 2006 Aug;4(2):111-21
pubmed: 16890539
Oncologist. 2004;9(2):188-96
pubmed: 15047923
Cancer Cell. 2012 Dec 11;22(6):765-80
pubmed: 23238013
Nat Rev Cancer. 2010 Mar;10(3):165-80
pubmed: 20179713
Eur Spine J. 2015 Oct;24(10):2173-81
pubmed: 25711910
Nature. 2010 May 27;465(7297):487-91
pubmed: 20445540
Oncogene. 2020 Nov;39(47):7063-7075
pubmed: 32989254
Nature. 2010 May 27;465(7297):483-6
pubmed: 20445537
Mol Cancer Res. 2010 Oct;8(10):1297-309
pubmed: 21047731
J Biol Chem. 2006 Oct 27;281(43):32574-86
pubmed: 16950769
Cancer Metastasis Rev. 2012 Jun;31(1-2):353-73
pubmed: 22549394
Blood. 2009 Aug 27;114(9):1803-12
pubmed: 19597185
Cell. 2008 Apr 4;133(1):38-52
pubmed: 18394988
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8
pubmed: 15067119